The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 02, 2018
Filed:
May. 12, 2016
Theraclone Sciences, Inc., Seattle, WA (US);
The Scripps Research Institute, La Jolla, CA (US);
International Aids Vaccine Initiative, New York, NY (US);
Po-Ying Chan-Hui, Bellevue, WA (US);
Katherine Doores, San Diego, CA (US);
Michael Huber, Zurich, CH;
Stephen Kaminsky, Bronx, NY (US);
Steven Frey, Redmond, WA (US);
Ole Olsen, Everett, WA (US);
Jennifer Mitcham, Redmond, WA (US);
Matthew Moyle, Redmond, WA (US);
Sanjay K. Phogat, Edison, NJ (US);
Dennis R. Burton, La Jolla, CA (US);
Laura Majorie Walker, San Diego, CA (US);
Pascal Raymond Georges Poignard, San Diego, CA (US);
Wayne Koff, Stony Brook, NY (US);
Melissa Danielle De Jean De St. Marcel Simek-Lemos, Brooklyn, NY (US);
THERACLONE SCIENCES, INC., Seattle, WA (US);
THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA (US);
INTERNATIONAL AIDS VACCINE INITIATIVE, New York, NY (US);
Abstract
The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.